Autoantibody profiling of alveolar rhabdomyosarcoma patients unveils tumor-associated antigens with diagnostic and prognostic significance
Authors:
Open Access
- 1 January 2021
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 10 (1) , 1954765
Abstract
Alveolar rhabdomyosarcoma (ARMS) is a highly aggressive subtype of childhood cancer for which efficacious treatments are needed. Immunotherapy represents a new therapeutic opportunity to pursue, but it requires the identification of worthwhile tumor antigens. Herein, we exploited the capacity of ARMS autoantibodies to recognize tumor self-antigens, probing human protein microarrays with plasma from ARMS patients and healthy subjects. We assessed the autoantibody response in ARMS, validated data with independent techniques, and estimated autoantibodies diagnostic and prognostic significance by receiver-operator characteristic curves (ROC), uni- and multivariate analysis. Of the 48 tumor antigens identified, General Transcription Factor II–I (GTF2i) and Protocadherin Gamma Subfamily C5 (PCDHGC5) were selected as candidate targets to validate tumor-restricted antigen expression and autoantibody reactivity through an independent technique and wider cohort of cases. GTF2i and PCDHGC5 overexpression was observed in tumor tissues compared to normal counterparts, and anti-GTF2i and -PCDHGC5 autoantibodies were found able to distinguish ARMS patients from healthy subjects as well as cases with different histology. Moreover, low levels of PCDHGC5 autoantibodies characterized patients with worse event-free survival and proved to be an independent negative prognostic factor. This approach provided the first comprehensive autoantibody profile of ARMS, gave novel insights into the immune response of this malignancy and paved the way toward novel potential antibody-based therapeutic applications suitable to improve the survival of ARMS patients.Keywords
Funding Information
- “Associazione Italiana per la Ricerca sul Cancro” (15813)
- Fondazione Cassa di Risparmio di Padova e Rovigo“ (17/09)
This publication has 47 references indexed in Scilit:
- The Pediatric Cancer Genome ProjectNature Genetics, 2012
- PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk StratificationJournal of Clinical Oncology, 2012
- Highly Specific Auto-Antibodies against Claudin-18 Isoform 2 Induced by a Chimeric HBcAg Virus-Like Particle Vaccine Kill Tumor Cells and Inhibit the Growth of Lung MetastasesCancer Research, 2011
- Gene Expression Profiling for Survival Prediction in Pediatric Rhabdomyosarcomas: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2010
- Robust-Linear-Model Normalization To Reduce Technical Variability in Functional Protein MicroarraysJournal of Proteome Research, 2009
- Robust-Linear-Model Normalization To Reduce Technical Variability in Functional Protein MicroarraysJournal of Proteome Research, 2009
- Identification of Tumor-associated Autoantigens for the Diagnosis of Colorectal Cancer in Serum Using High Density Protein MicroarraysMolecular & Cellular Proteomics, 2009
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational ResearchClinical Cancer Research, 2009
- Analysis of Prognostic Factors in Patients With Nonmetastatic Rhabdomyosarcoma Treated on Intergroup Rhabdomyosarcoma Studies III and IV: The Children's Oncology GroupJournal of Clinical Oncology, 2006
- Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcomaNature Genetics, 1993